Trial Profile
A randomized, double-blind, placebo-controlled investigation of the safety, tolerability and pharmacokinetics of 1% SPL7013 nasal spray in healthy volunteers when administered four times a day for 14 days
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2021
Price :
$35
*
At a glance
- Drugs Astodrimer (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Starpharma
- 17 Aug 2021 According to a Starpharma media release, this study was conducted at Linear Clinical Research in Western Australia.
- 17 Aug 2021 Results presented in Starpharma media release,
- 08 Jul 2021 Status changed from not yet recruiting to completed.